Your news release is automatically posted to your site once it hits the wire.Saves you the time and cost of getting the news posted by a webmaster.Automatically emails releases to your databases.
Choose automatic or manual mode. Automatic extraction of news from the wire, uploaded to your site. Tied in with the email database to automatically send the release to your list(s).
|10/21/2002 11:13:17 AM ET||News Release Index |
|Oncolytics Biotech to Present at
4th Annual Techvest LLC Healthcare Conference
|Boston, MA, October 21, 2002 --- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC), (NASDAQ: ONCY), will be presenting at Techvest’s 4th Annual Healthcare Conference in Boston on Tuesday, October 22 at 4:45 p.m. (EST) at the Boston Long Wharf Marriott Hotel. |
The presentation will be webcast live from the conference, and can be accessed through the Oncolytics website at www.oncolyticsbiotech.com. From the Oncolytics home page, click on Techvest Presentation, which will take you to the Techvest audio broadcast. You can also go directly to the Techvest audio broadcast site at http://www.visualwebcaster.com/event.asp?id=8348.
Here is what you will need to listen to the broadcast:
• At least a 28.8Kbps connection to the Internet
• Windows Media Player (downloadable from the site)
The broadcast will also be available on the Oncolytics website for 30 days following the presentation.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of the human reovirus (REOLYSIN®) as a potential cancer therapeutic. Oncolytics’ researchers have demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells derived from many types of cancer including breast, prostate, pancreatic and brain tumours. Research has also yielded successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that there were no toxicology-related issues with the administration of the reovirus, and that the reovirus demonstrated activity in injected tumours. Oncolytics is currently conducting a T2 prostate cancer trial, and a Phase I/II recurrent malignant glioma (brain cancer) trial.
This show airing time is subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risk, delays, uncertainties and other factors not under the Company’s control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
Oncolytics Biotech Inc.
210, 1167 Kensington Cr NW
Calgary, Alberta T2N 1X7
The Equicom Group Inc.
20 Toronto Street
Toronto, Ontario M5C 2B8
Tel: 416.815.0700 ext. 222
For United States:
The Investor Relations Group
Gino De Jesus or Dian Griesel, Ph.D.
50 Pine Street, 6th Floor
New York, NY 10005
News Release Index
You are viewing our Quote and Chart Demo using ticker symbol T.ONC